The correlation between plasma fibrinogen levels and the clinical features of patients with ovarian carcinoma

Journal of International Medical Research

Volumn 35, Issue 5, 2007, Pages 678-684

  Ma, Y ^a   Qian, Y ^a   Lv, W ^a  

^a ZHEJIANG UNIVERSITY   (China)

Author keywords

Blood coagulation tests; CA 125 antigen; Fibrinogen; Ovarian neoplasms

Indexed keywords

CA 125 ANTIGEN; FIBRINOGEN;

ADULT; AGE; AGED; ARTICLE; BLOOD GROUP; BODY MASS; CANCER CLASSIFICATION; CANCER STAGING; CARCINOMATOUS PERITONITIS; CLINICAL FEATURE; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; FIBRINOGEN BLOOD LEVEL; HUMAN; MAJOR CLINICAL STUDY; METASTASIS POTENTIAL; OVARY CARCINOMA; OVARY TUMOR; PARTIAL THROMBOPLASTIN TIME; PREOPERATIVE EVALUATION; PROTHROMBIN TIME; RETROSPECTIVE STUDY; THROMBIN TIME;

EID: 35348901381     PISSN: 03000605     EISSN: None     Source Type: Journal    
DOI: 10.1177/147323000703500512     Document Type: Article

References (27)

1. Rickles FR, Levine M, Edwards RL: Hemostatic alterations in cancer patients. Cancer Metastasis Rev 1992; 11: 237-248 (DOI: 10.1007/BF01307180).
2. Zacharski LR, Memoli VA, Ornstein DL, et al: Tumor cell procoagulant and urokinase expression in carcinoma of the ovary. J Natl Cancer Inst 1993; 85: 1225-1230.
3. Naschitz JE, Yeshurun D, Lev LM: Thromboembolism in cancer. Changing trends. Cancer 1993; 71: 1384-1390.
4. Borgono CA, Diamandis EP: The emerging roles of human tissue kallikreins in cancer. Nat Rev Cancer 2004; 4: 876-890 (DOI: 10.1038/ nrc1474).
5. Winter PC: The pathogenesis of venous thromboembolism in cancer, emerging links with tumour biology. Hematol Oncol 2006; 24: 126-133.
6. Lee JH, Ryu KW, Kim S, et al: Preoperative plasma fibrinogen levels in gastric cancer patients correlate with extent of tumor. Hepatogastroenterology 2004; 51: 1860-1863.
7. Yamashita H, Kitayama J, Nagawa H: Hyperfibrinogenemia is a useful predictor for lymphatic metastasis in human gastric cancer. Jpn J Clin Oncol 2005; 35: 595-600.
8. Jones JM, McGonigle NC, McAnespie M, et al: Plasma fibrinogen and serum C-reactive protein are associated with non-small cell lung cancer. Lung Cancer 2006; 53: 97-101.
9. Palumbo JS, Kombrinck KW, Drew AF, et al: Fibrinogen is an important determinant of the metastatic potential of circulating tumor cells. Blood 2000; 96: 3302-3309.
10. Hernandez E, Donohue KA, Anderson LL, et al: The significance of thrombocytosis in patients with locally advanced cervical carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol 2000; 78: 137-142.
11. Symbas NP, Townsend MF, El-Galley R, et al: Poor prognosis associated with thrombocytosis in patients with renal cell carcinoma. BJU Int 2000; 86: 203-207.
12. Shimada H, Oohira G, Okazumi S, et al: Thrombocytosis associated with poor prognosis in patients with esophageal carcinoma. J Am Coll Surg 2004; 198: 737-741.
13. Ikeda M, Furukawa H, Imamura H, et al: Poor prognosis associated with thrombocytosis in patients with gastric cancer. Ann Surg Oncol 2002; 9: 287-291.
14. Koh SC, Khalil R, Lim FK, et al: The association between fibrinogen, von Willebrand Factor, antithrombin III, and D-dimer levels and survival outcome by 36 months from ovarian cancer. Clin Appl Thromb Hemost 2006; 12: 3-8.
15. Sampson MT, Kakkar AK: Coagulation proteases and human cancer. Biochem Soc Trans 2002; 30: 201-207 (DOI: 10.1042/ BST0300201).
16. Topalak O, Saygili U, Soyturk M, et al: Serum, pleural effusion, and ascites CA-125 levels in ovarian cancer and nonovarian benign and malignant diseases: a comparative study. Gynecol Oncol 2002; 85: 108-113.
17. Saygili U, Guclu S, Uslu T, et al: The effect of ascites, mass volume, and peritoneal carcinomatosis on serum CA125 levels in patients with ovarian carcinoma. Int J Gynecol Cancer 2002; 12: 438-442.
18. Nagy JA, Meyers MS, Masse EM, et al: Pathogenesis of ascites tumor growth: fibrinogen influx and fibrin accumulation in tissues lining the peritoneal cavity. Cancer Res 1995; 55: 369-375.
19. Palumbo JS, Potter JM, Kaplan LS, et al: Spontaneous hematogenous and lymphatic metastasis, but not primary tumor growth or angiogenesis, is diminished in fibrinogen-deficient mice. Cancer Res 2002; 62: 6966-6972.
20. Tsai AW, Cushman M, Rosamond WD, et al: Coagulation factors, inflammation markers, and venous thromboembolism: the longitudinal investigation of thromboemholism etiology (LITE). Am J Med 2002; 113: 689-690.
21. Marchi R, López Ramirez Y, Nagaswami C, et al: Haemostatic changes related to fibrin formation and fibrinolysis during the first trimester in normal pregnancy and in recurrent miscarriage. Thromb Haemost 2007; 97: 552-557.
22. Cushman M, Tsai AW, White RH, et al: Deep vein-thrombosis and pulmonary embolism in two cohorts: the longitudinal investigation of thromboembolism etiology. Am J Med 2004; 117: 19-25.
23. Hirohashi T, Yoshinaga K, Sakurai T, et al: Study of the echocardiographic diagnosis of acute pulmonary thromboembolism and risk factors for venous thromboembolism. J Cardiol 2006; 47: 63-71.
24. Tateo S, Mereu L, Salamano S, et al: Ovarian cancer and venous thromboembolic risk. Gynecol Oncol 2005; 99: 119-125.
25. Streiff MB, Segal J, Grossman SA, et al: ABO blood group is a potent risk factor for venous thromboembolism in patients with malignant gliomas. Cancer 2004; 100: 1717-1723.
26. Tirado I, Mateo J, Soria JM, et al: The ABO blood group genotype and factor VIII levels as independent risk factors for venous thromboembolism. Thromb Haemost 2005; 93: 468-474.
27. Matsuura Y, Robertson G, Marsden DE, et al: Thromboembolic complications in patients with clear cell carcinoma of the ovary. Gynecol Oncol 2007; 104: 406-410 (Epub 2 October 2006).